<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lederman, Lynne</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Thomas, Gregory S.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Monoclonal Antibody to PCSK9 Offers New Approach to Treating Hypercholesterolemia</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2013-08-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">16-17</style></pages><abstract><style  face="normal" font="default" size="100%">Hypercholesterolemia, particularly an increased level of low-density lipoprotein cholesterol (LDL-C) is associated with elevated cardiovascular (CV) risk. Individuals with genetic lifelong lower levels of LDL-C are associated with a reduced risk of CV events. In addition, the reduction in coronary heart disease (CHD) risk is proportional to the decrease in LDL-C over the time period of LDL-C reduction. Statins are often used to therapeutically lower LDL-C levels, but individuals with lifelong lower LDL-C levels due to genetic variants have three times the protection from CHD as do those who begin statin therapy later in life.</style></abstract><number><style face="normal" font="default" size="100%">7</style></number><volume><style face="normal" font="default" size="100%">13</style></volume></record></records></xml>